Evidence map›Paper›PMID 29166232›Full record

ArticleThe New England journal of medicine2017

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Bruce Neal, Vlado Perkovic, David R Matthews

4 registry-linked trialsAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 307 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
307citing papers in PubMed, 20 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04203927 early_phase1unknown statusstarted 2020, after this paper: background citation

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Ran2020Enrolled50Registered outcomes4Posted comparisons0ConditionsInsulin Sensitivity, Type2 DiabetesArmsempagliflozin 25 mg
PMID 26981940PMID 25633683PMID 27299675PMID 24711523PMID 23459195PMID 21617098PMID 21047922PMID 20978231PMID 20380649PMID 19996061PMID 16386091PMID 16308832other papers from this trial
Open the trial in the graph
NCT05719714 phase1 / phase2active not recruitingstarted 2024, after this paper: background citation

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Ran2024Enrolled18Registered outcomes5Posted comparisons0ConditionsChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Kidney DiseasesArmsDapagliflozin 10 MG [Farxiga]
PMID 29526832PMID 29133604PMID 29762782PMID 10716471PMID 15504931PMID 16461840PMID 18760751PMID 21262990PMID 21817129PMID 24218128PMID 25370599PMID 25533966other papers from this trial
Open the trial in the graph
NCT03717194 phase3completednot on this mapstarted 2019, after this paper: background citation

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, to Evaluate the Effect of Ertugliflozin on Cardiac Function in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control and Stage B Heart Failure

TypeinterventionalSponsorSoo LimRan2019 to 2023Enrolled102ConditionsType2 Diabetes, Heart FailureArmsErtugliflozin, Placebo
NCT07325201 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report

TypeinterventionalSponsorHealthPartners InstituteRan2026 to 2030Enrolled80ConditionsType 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic KetoacidosisArmsSotagliflozin initiation
3 · Its place in the literature

Who cites it

307 citing papers in PubMed, 20 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

247 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Bruce NealGeorge Institute for Global Health, Sydney, NSW, Australia
Vlado PerkovicGeorge Institute for Global Health, Sydney, NSW, Australia
David R MatthewsUniversity of Oxford, Oxford, United Kingdom

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CanagliflozinDiabetes Mellitus, Type 2GlucosidesHumansHypoglycemic AgentsKidneySodium-Glucose Transporter 2CanagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2

Identifiers

PMID29166232

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.